Hotgen Biotech Co., Ltd (SHA: 688068), a biopharmaceutical company based in China, has announced that it has received clinical trial approval from the U.S. Food and Drug Administration (FDA) for its innovative drug candidate, SGC001.
SGC001 is an investigational monoclonal antibody (mAb) co-developed with Capital Medical University, designed for the acute treatment of acute myocardial infarction (AMI). This novel antibody drug is poised to be the first of its kind to enter clinical trials globally, targeting this critical medical indication, with no existing antibody drugs currently in the clinic or on the market for this specific use.- Flcube.com
